EUCTR2014-002168-34-CZ
Active, not recruiting
Phase 1
Study To Determine Efficacy of Aflibercept For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
Doc. MUDr. Petr Kolár, PhD, Ocní klinika FN Brno0 sites45 target enrollmentSeptember 15, 2014
DrugsEylea
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Doc. MUDr. Petr Kolár, PhD, Ocní klinika FN Brno
- Enrollment
- 45
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Ability to provide written informed consent and comply with study assessments for the full duration of the study.
- •2\) Men and women \= 50 years old; women has to be postmenopausal
- •3\) Definite characteristic signs of retinal angiomatous proliferation secondary to wet AMD as determined by clinical signs (retinal oedema, subretinal fluid, sub RPE fluid, retinal or subretinal hemorrhage) and angiography (minimally classic leakage on fluorescein angiography)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 15
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 30
Exclusion Criteria
- •A subject who meets any of the following criteria will be excluded from the study.
- •1\) Prior treatment with ranibizumab, bevacizumab, pegaptanib, verteporfin, external\-beam radiation therapy, or transpupillary thermotherapy in the study eye
- •2\) Previous subfoveal focal laser photocoagulation involving the foveal centre in the study eye
- •3\) Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month preceding baseline
- •4\) History of pars plana vitrectomy, submacular surgery, or other surgical intervention for AMD in the study eye
- •5\) Previous participation in any studies of investigational drugs within 1 month preceding baseline
- •6\) Subjects with scar or fibrosis making up \>50% of the total lesion or scar, fibrosis, or atrophy involving the centre of the fovea in the study eye.
- •7\) Subjects with clinical evidence of diabetic macular oedema, diabetic retinopathy or any retinal vascular disease other than AMD in either eye.
- •8\) Subjects with other causes of CNV in the study eye.
- •9\) Subjects with history of retinal detachment or treatment or surgery for retinal detachment in the study eye.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Investigation of clinical efficacy for Aflibercept in patients with polypoidal choroidal vasculopathy (PCV)Polypoidal Choroidal VasculopathyJPRN-UMIN000011091Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University50
Recruiting
Phase 4
Prospective study evaluating aflibercept in patients with recurrent or prolonged diabetic macular edema after vitrectomyDiabetic macular edemaJPRN-UMIN000016036Kyushu university30
Completed
Not Applicable
Investigation of clinical efficacy of aflicbercept in patients with polypoidal choroidal vasculopathy (PCV) with resistance of ranibizumabPolypoidal choroidal vasculopathyJPRN-UMIN000012493Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo30
Completed
Phase 2
Evaluation of safety and efficacy to abatacept treatment of patients with HBV-related acute liver failure.-Pilot StudyJPRN-UMIN000016148Hiroshima liver study group5
Recruiting
Not Applicable
Multi-Center Study of Aflibercept Therapy for Neovascular Age-Related Macular Degeneration Using Trreat and Extend Strategyeovascular age-related macular degenerationJPRN-UMIN000016152Tokyo Women's Medical University200